Supplement industry unites around innovation-forward interpretation for ‘dietary substance’

The supplement industry is largely united in advocating for a broad, innovation-driven interpretation of the term “dietary substance” under DSHEA, urging the FDA to recognize substances beyond those traditionally present in the food supply. Stakeholders agree that manufacturing methods alone should not redefine ingredient identity or trigger new regulatory hurdles, instead emphasizing safety and measurable characteristics. Industry groups call for clear, science-based criteria for ingredient identity and sameness, particularly for complex substances like proteins and probiotics, and support transparent labeling that distinguishes between traditional and modern production techniques. The consensus is that regulatory focus should remain on safety and evidence, enabling innovation while maintaining rigorous oversight through existing mechanisms.